



(51) International Patent Classification:

C07K 16/28 (2006.01) *C12N 5/12* (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:

PCT/IB2014/061166

(22) International Filing Date:

2 May 2014 (02.05.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/820,604 7 May 2013 (07.05.2013) US
61/981,115 17 April 2014 (17.04.2014) US


(71) Applicant: RINAT NEUROSCIENCE CORP. [US/US];
230 East Grand Avenue, South San Francisco, California
94080 (US).(72) Inventors: CHAPARRO RIGGERS, Javier, Fernando;
904 Peninsula Avenue, San Mateo, California 94401 (US).
FORGIE, Alison, Jane; c/o Rinat Neuroscience Corp.,
230 East Grand Avenue, South San Francisco, California
94080 (US). LAVALLIE, Edward, Roland; 113 Ann Lee
Road, Harvard, Massachusetts 01451 (US). LIN, Chia-
Yang; 940 Sycamore Drive, Palo Alto, California 94303
(US). MOSYAK, Lidia; 92 Littlefield Road, Newton,
Massachusetts 02459 (US). ROSSI, Andrea; 251 Downey
Street, San Francisco, California 94117 (US). VAN
BLARCOM, Thomas, John; 6415 Chelton Drive, Oak-
land, California 94611 (US).(74) Agents: KLEIMAN, Gabriel, L. et al.; Pfizer Inc., 235
East 42nd Street, Mail Stop 235/9/64, New York, New
York 10017 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF



(57) Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.



- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))* — *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

16 April 2015

Published:

- *with international search report (Art. 21(3))*
- *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*